We are Minomic
We have developed a new non-invasive test for prostate cancer, called MiCheck.
It is more specific than existing tests, therefore, once commercialised, would reduce
the rate of false positive results and unnecessary biopsies.
The problemExisting tests for prostate cancer are unreliable.
3 in 5 results are false positives
There are approximately 14 different PSA tests in use today. They all have a common problem in that elevated PSA levels — which these tests measure — can result from causes other than cancer. This means that 3 in 5 men diagnosed with Prostate Cancer are false positives.
A product of inaccuracy, overdiagnosis results in many avoidable biopsies, tests and treatments. The costs to the patient and the system add up.
Too many false positives
A false positive can be a deeply traumatic experience. Fortunately these can be largely avoided with more accurate diagnostics.
Unpleasant or painful testing procedures
Digital rectal examinations and biopsies can be significant barriers to testing for those at risk.
- Better diagnostic
- More accurate
- Fewer false positives
The solutionThe MiCheck test is more specific than a PSA test and requires only a blood sample.
The MiCheck Test is quick, non-invasive and will be performed in standard pathology labs. Those who need treatment will get it sooner, and those who don't need not suffer the trauma of false positives, nor add costs to the system. Ultimately, we believe that more lives can be saved.
And it's almost ready to go…
The Minomic Test is in the late development stage
Proof of Principle
Proof of Concept
Want to know when it's ready or learn more?
We'll be providing more and detailed information as we reach our milestones